Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau <scp>PET</scp> Clocks
These findings suggest that the plasma Aβ42/Aβ40 may be useful in identifying individuals with very low levels of amyloid pathology, whereas p-tau, GFAP, and NfL may be useful in staging disease progression. ANN NEUROL 2025;98:508-523.
Authors
- Benjamin Saef
- Marta Milà‐Alomà (ORCID: https://orcid.org/0000-0002-5687-4597)
- Michael V. Baratta (ORCID: https://orcid.org/0000-0001-7273-1994)
- Duygu Tosun (ORCID: https://orcid.org/0000-0001-8644-7724)
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Anthony W. Bannon
- David Raunig (ORCID: https://orcid.org/0000-0003-4549-1280)
- Kyle Ferber (ORCID: https://orcid.org/0000-0002-4730-6993)
- Janaky Coomaraswamy
- Yulia Mordashova
- Jeffrey L. Dage (ORCID: https://orcid.org/0000-0002-2192-1699)
- Erin G. Rosenbaugh (ORCID: https://orcid.org/0000-0002-3909-9760)
- Carrie E. Rubel (ORCID: https://orcid.org/0000-0003-1371-2536)
- Gallen Triana‐Baltzer (ORCID: https://orcid.org/0000-0003-0612-1236)
- Hartmuth C. Kolb (ORCID: https://orcid.org/0000-0003-2414-5792)
- Kellen K. Petersen (ORCID: https://orcid.org/0000-0003-3195-3456)
- Emily A. Meyers (ORCID: https://orcid.org/0000-0002-0886-6218)
- Suzanne E. Schindler (ORCID: https://orcid.org/0000-0002-1680-1465)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Yan Li (ORCID: https://orcid.org/0000-0003-3673-181X)
- Leslie M. Shaw (ORCID: https://orcid.org/0000-0002-7650-1210)
- William Z. Potter
- Ziad S. Saad
- Lei Du‐Cuny
- Martin Sabandal
- Isabella Hausle
Institutions
- Alzheimer's Association (US)
- Biogen (United States) (US)
- Johnson & Johnson (United States) (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Foundation for the National Institutes of Health (US)
- Sahlgrenska University Hospital (SE)
- University of California System (US)
- AbbVie (United States) (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- UK Dementia Research Institute (GB)
- AbbVie (Germany) (DE)
- Takeda (United States) (US)
- National Hospital for Neurology and Neurosurgery (GB)
- Northern California Institute for Research and Education (US)
- Indiana University School of Medicine
- University College London (GB)
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1002/ana.27285
- Citations
- 14
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 20.60
Funders
- Foundation for the National Institutes of Health
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Fujirebio US
- Eisai
- Göteborgs Universitet
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research
- National Institute on Aging